All In Biotech

NDA 215395 · Invagen Pharms

Lanreotide Acetate

Lanreotide Acetate · Subcutaneous

Discontinued

Last checked: Nov 20, 2026Latest source record: Sep 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Dec 17, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

84

39 Phase 3, 6 recruiting

FAERS reports

3,387

3,167 serious, 1,185 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 1, 2024.

Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. ( 1.2 ) the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. ( 1.3 ) 1.1 Acromegaly Lanreotide Injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal. 1.2 Gastroenteropancreatic Neuroendocrine Tumors Lanreotide Injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. 1.3 Carcinoid Syndrome Lanreotide Injection is indicated for the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.

Mechanism: Lanreotide, the active component of Lanreotide Injection, is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 16, 2024 Supplement 7 · Efficacy LetterLabel
  • Dec 17, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
3 products under this application
  • LANREOTIDE ACETATE · LANREOTIDE ACETATE EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML) · SOLUTION, SUBCUTANEOUS · Discontinued
  • LANREOTIDE ACETATE · LANREOTIDE ACETATE EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) · SOLUTION, SUBCUTANEOUS · Discontinued
  • LANREOTIDE ACETATE · LANREOTIDE ACETATE EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) · SOLUTION, SUBCUTANEOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Lanreotide" as an intervention, any sponsor and status, largest first.

All 84 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death1,038
  • off label use943
  • diarrhoea596
  • fatigue454
  • abdominal pain347
  • nausea328
  • malignant neoplasm progression327
  • weight decreased281
  • malaise270
  • asthenia269
  • dizziness237
  • vomiting234

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20062
20091
20101
20111
20123
20133
20143
20151
20162
20176
201829
201941
202058
2021198
2022338
2023868
2024666
2025753
2026413

Recalls

2 FDA enforcement reports for this application.

  • Mar 13, 2026 · Class II · Ongoing

    Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

  • Jan 2, 2026 · Class II · Ongoing

    Presence of Particulate Matter.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lanreotide Acetate (Lanreotide Acetate)

2024 spending

$8.7M

Beneficiaries

187

1,030 claims

Per beneficiary

$46,719

$16,248.29 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,587,960
2023$6,935,856
2024$8,736,380

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 222 on PubMed

Sponsor: Invagen Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.